Multi-year funding will advance oral health, as oral diseases are among the most prevalent and overlooked noncommunicable diseases impacting 3.7 billion people globally.1 ...
On January 16, Barclays analyst Lauren Lieberman raised Barclays’ price target on Colgate-Palmolive Company (NYSE:CL) to $83 ...
Colgate-Palmolive Company (NYSE:CL) is among the 7 Best Beauty Stocks to Buy Right Now. On January 8, 2026, TheFly reported ...
On January 7, Piper Sandler upgraded Colgate-Palmolive Company (NYSE:CL) to Overweight from Neutral and raised its price ...
Colgate-Palmolive (CL) is a Dividend King with strong dividend safety, high margins, and consistent long-term execution, currently trading at a reasonable 21.6x earnings. CL’s science-based innovation ...
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $87.77, with a ...
Press Trust of India on MSN
Colgate-Palmolive’s Integrated CSR and ESG Initiatives Create an Impact on Health, Dignity and Community Well-Being
Colgate-Palmolive’s Integrated CSR and ESG Initiatives Create an Impact on Health, Dignity and Community Well-Being ...
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Colgate-Palmolive ...
Morgan Stanley analysts named Colgate-Palmolive their top pick in the household and personal care segment on Thursday, and ...
The big shareholder groups in Colgate-Palmolive Company (NYSE:CL) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have ...
Colgate-Palmolive and Introgen Therapeutics, Austin, Tex, biotechnology company, announce alliance to incorporate gene therapy into mouthwashes, gels and similar products to treat and prevent oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback